Federal grants to Siteone Therapeutics, Inc.
Siteone Therapeutics, Inc. in South San Francisco, California received $8.5 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Drug Use and Addiction Research Programs, with $5.3 million. In fiscal 2025 more was taken back from its awards than added, a net -$178,118.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$8.5 million
- Awards4
- Awarded in FY 2025-$178,118
- Largest award$5.3 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $2.2 million |
| FY 2022 | 2 | $1.6 million |
| FY 2023 | 1 | $5.3 million |
| FY 2024 | 0 | -$538,457 |
| FY 2025 | 0 | -$178,118 |
Programs that fund Siteone Therapeutics, Inc.
| Program | Awards | Amount |
|---|---|---|
| Drug Use and Addiction Research Programs | 1 | $5.3 million |
| Vision Research | 1 | $1.5 million |
| Cardiovascular Diseases Research | 1 | $1.2 million |
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 1 | $453,360 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $8.5 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Development of a potent and selective NAV1.8 inhibitor for the treatment of acute and chronic pain with the goal of reducing opioid use and preventing opioid use disorders - project summary voltage-gated sodium ion channels (NAVS) are required for the transmission of electrical signals along pain SE | Drug Use and Addiction Research Programs | May 4, 2023 | $5.3 million |
| Development of a selective inhibitor of NAV1.7 for the treatment of ocular pain - project summary the absence of safe and effective strategies for the management of ocular pain is motivating the development of a novel topical drug suitable for patient self-administration. Conventional local anesthet | Vision Research | August 27, 2021 | $1.5 million |
| Development of NAV1.7 selective inhibitors for the treatment of chronic cough - project summary chronic cough, or cough that persists for more than eight weeks, is a condition that is often associated with diseases such as chronic obstructive pulmonary disorder (COPD), asthma, idiopathic pulmonary f | Cardiovascular Diseases Research | May 7, 2021 | $1.2 million |
| Discovery of NAV1.7 inhibitors for the treatment of pain | Extramural Research Programs in the Neurosciences and Neurological Disorders | May 15, 2021 | $453,360 |
Questions people ask
How much federal grant money does Siteone Therapeutics, Inc. get?
$8.5 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Siteone Therapeutics, Inc. the most?
The Department of Health and Human Services, with $8.5 million in 4 awards.
What is Siteone Therapeutics, Inc.'s largest federal grant?
$5.3 million under Drug Use and Addiction Research Programs, with its first action in the period on May 4, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Siteone Therapeutics, Inc.?
Its largest are Drug Use and Addiction Research Programs, Vision Research and Cardiovascular Diseases Research.
Other grant recipients in South San Francisco
- City of South San Francisco
- South San Francisco Housing Authority
- Enable Biosciences Inc
- Reacx Pharmaceuticals, Inc.
- Centivax, Inc.
- Isono Health, Inc.
- Superfluid DX, Inc.
- Khloris Biosciences, Inc.
Largest federal grant recipients in California · Federal grants in California